Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-04-08
2004-08-10
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S004300, C514S866000, C536S001110, C536S017400, C536S017600, C536S018400
Reexamination Certificate
active
06774112
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the generation of crystalline amino acid complexes from amorphous C-aryl glucosides which are useful for the treatment of diabetes, especially type II diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases.
BACKGROUND OF THE INVENTION
Approximately 100 million people worldwide suffer from type II diabetes (NIDDM), which is characterized by hyperglycemia due to excessive hepatic glucose production and peripheral insulin resistance, the root causes for which are as yet unknown. Hyperglycemia is considered to be the major risk factor for the development of diabetic complications, and is likely to contribute directly to the impairment of insulin secretion seen in advanced NIDDM. Normalization of plasma glucose in NIDDM patients would be predicted to improve insulin action, and to offset the development of diabetic complications. An inhibitor of the sodium-dependent glucose transporter SGLT2 in the kidney is expected to aid in the normalization of plasma glucose levels, and perhaps body weight, by enhancing glucose excretion.
Hyperglycemia is a hallmark of type II diabetes (NIDDM); consistent control of plasma glucose levels in diabetes can offset the development of diabetic complications and beta cell failure seen in advanced disease. Plasma glucose is normally filtered in the kidney in the glomerulus and actively reabsorbed in the proximal tubule. SGLT2 appears to be the major transporter responsible for the reuptake of glucose at this site. The O-glucoside SGLT specific inhibitor phlorizin or closely related analogs inhibit this reuptake process in diabetic rodents and dogs resulting in normalization of plasma glucose levels by promoting glucose excretion without hypoglycemic side effects. Long term (6 month) treatment of Zucker diabetic rats with an O-glucoside SGLT2 inhibitor has been reported to improve insulin response to glycemia, improve insulin sensitivity, and delay the onset of nephropathy and neuropathy in these animals, with no detectable pathology in the kidney and no electrolyte imbalance in plasma. Selective inhibition of SGLT2 in diabetic patients would be expected to normalize plasma glucose by enhancing the excretion of glucose in the urine, thereby improving insulin sensitivity, and delaying the development of diabetic complications.
The present invention relates to C-aryl glucosides which are inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2) and to a method for treating diabetes, especially type II diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases, employing such C-aryl glucosides alone or in combination with one, two or more other type antidiabetic agent and/or one, two or more other type therapeutic agents such as hypolipidemic agents.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5444050 (1995-08-01), Kogan et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5663377 (1997-09-01), Curley et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 0221025 (1986-10-01), None
patent: 2596393 (1986-04-01), None
patent: 2205837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO98/31697 (1998-07-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO01/16147 (2001-08-01), None
Johannsson et al., J. Clin. Endocrinol. Metab., 82:727-34 (1997).
Benhaddou et al., Carbohydr. Res., 260:243-250 (1994).
Murakami et al., Diabetes 47:1841-1847 (1998).
Hughes et al., Biochemistry, 38(36):11597-11603 (1999).
Yamada et al., Bioorg. & Med. Chem. Lett., 8:1537-1540 (1998).
Ashworth et al., Bioorg. & Med. Chem. Lett., 6:1163-1166 (1996).
Ashworth et al., Bioorg. & Med. Chem. Lett., 6:2745-2748 (1996).
Biller et al., J. Med. Chem., 31(10):1869-1871 (1988).
Biller et al., Current Pharmaceutical Design, 2:1-40 (1996).
Ortiz De Montellano et al., J. Med. Chem., 20:243-249 (1977).
Corey et al., J. Am. Chem. Soc., 98:1291-1293 (1976).
McClard et al., J. Am. Chem. Soc., 109:5544-5545 (1987).
Sorbera et al., Drugs of the Future, 24:9-15 (1999).
Nicolosi et al., Atherosclerosis, 137(1):77-85 (1998).
Ghiselli, Cardiovasc. Drug Rev., 16(1):16-30 (1998).
Smith et al., Bioorg. Med. Chem. Lett., 6(1):47-50 (1996).
Krause et al., Inflammation: Mediators Pathways, Publisher: CRC, Boca Raton, Fla., p. 173-98 (1995).
Sliskovic et al., Curr. Med. Chem. 1(3):204-25 (1994).
Stout et al., Chemtracts- Org. Chem., 8(6):359-62 (1995).
Salisbury et al., Atherosclerosis, 115:45-63 (1995).
Rosenblum et al., J. Med. Chem., 41:973-980 (1998).
Hara, Drugs of the Future, 24:425-430 (1999).
Sendobry et al., Brit. J. Pharmacology 120:1199-1206 (1997).
Cornicelli et al., Current Pharmaceutical Design, 5:11-20 (1999).
Capson, PhD Dissertation, Jun., 1987, Dept. Med. Chem., U of Utah, pp16,17,40-43,48-51.
Bristol--Myers Squibb Company
Khare Devesh
O'Brien Maureen P.
Provoost Jonathan N.
Vanatten Mary
LandOfFree
Amino acid complexes of C-aryl glucosides for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid complexes of C-aryl glucosides for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid complexes of C-aryl glucosides for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3356231